Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Equity Average: 2010-2025

Historic Equity Average for Aytu Biopharma (AYTU) over the last 16 years, with Jun 2025 value amounting to $23.3 million.

  • Aytu Biopharma's Equity Average fell 26.77% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year decrease of 26.77%. This contributed to the annual value of $23.3 million for FY2025, which is 30.40% down from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Equity Average is $23.3 million, which was down 30.40% from $33.5 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Equity Average ranged from a high of $116.3 million in FY2021 and a low of $23.3 million during FY2025.
  • Moreover, its 3-year median value for Equity Average was $33.5 million (2024), whereas its average is $32.9 million.
  • As far as peak fluctuations go, Aytu Biopharma's Equity Average soared by 127.79% in 2021, and later crashed by 54.00% in 2023.
  • MRY analysis of 5 years shows Aytu Biopharma's Equity Average stood at $116.3 million in 2021, then fell by 21.80% to $90.9 million in 2022, then tumbled by 54.00% to $41.8 million in 2023, then fell by 19.83% to $33.5 million in 2024, then crashed by 30.40% to $23.3 million in 2025.
  • Its Equity Average was $23.3 million in FY2025, compared to $33.5 million in FY2024 and $41.8 million in FY2023.